Advertisement

Topics

Codexis hunts next Big Pharma license deal for biocatalyst engineering platform

04:39 EDT 13 Mar 2018 | in-PharmaTechnologis

With GSK and Merck & Co. no longer on the books, Codexis is looking to secure its next CodeEvolver license deal.

Original Article: Codexis hunts next Big Pharma license deal for biocatalyst engineering platform

NEXT ARTICLE

More From BioPortfolio on "Codexis hunts next Big Pharma license deal for biocatalyst engineering platform"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

GlaxoSmithKline
GlaxoSmithKline is the third largest pharmaceutical company in the world, based on annual sales, which reached $37,134m in 2009. Spread over 100 countries, GSK employs 96,500 people, 13,000 of which are dedicated to research and development of the the ...

Merck and Co
Merck & Co is the 7th largest pharmaceutical company in the world based on annual sales, which reached $25,236m in 2009. They have developed 14 vaccines and over 40 prescription products in the major therapeutic areas of cardiovascular disease, respi...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...